OM Stock Forecast: Outset Medical, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Outset Medical, Inc. hold a median 12-month price target of $7 — +149.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 52 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Outset Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +149.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Feb 2026 | BTIG | Maintains | Buy | $17 → $15 |
| 7 Jan 2026 | Stifel | Maintains | Buy | — |
| 16 Dec 2025 | BTIG | Reiterates | Buy | — |
| 11 Nov 2025 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 11 Nov 2025 | Stifel | Maintains | Buy | — |
| 19 Aug 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 7 Aug 2025 | RBC Capital | Maintains | Sector Perform | — |
| 21 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 8 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 7 Jan 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 8 Aug 2024 | RBC Capital | Downgrade | Sector Perform | — |
| 8 Aug 2024 | TD Cowen | Maintains | Buy | — |
| 21 June 2024 | RBC Capital | Upgrade | Outperform | — |
| 8 Apr 2024 | BTIG | Initiates | Buy | — |
| 12 Jan 2024 | RBC Capital | Downgrade | Sector Perform | — |
| 4 Dec 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 13 Oct 2023 | B of A Securities | Downgrade | Underperform | — |
| 13 Oct 2023 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OM.
This page is one stock. Monday covers all of them.
OM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Outset Medical, Inc. returned −36.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.5×
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 80% of US stocks
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 42.0%
- Operating margin
- −51.2%
- Net margin
- −58.3%
Higher than 52% of US stocks
Higher than 18% of US stocks
Higher than 9% of US stocks
- Return on equity
- −63.0%
- Return on assets
- −15.4%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Outset Medical, Inc. has a market value of $54.9M and an enterprise value of $23.1M.
Revenue in the twelve months to 30 June 2026: $117.8M. The latest quarter grew 0.7% year on year.
Net income over the same four quarters: −$74.3M, a −63.1% net margin.
Diluted earnings per share, trailing twelve months: −$4.09.
Free cash flow in the twelve months to 30 June 2026: −$38.9M.
Outset Medical, Inc. employs 310 people — $380K of revenue per employee.
Data provided by Twelve Data
OM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OM’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Outset Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OM
What is the OM stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Outset Medical, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OM stock a buy right now?
Of the 3 analysts covering Outset Medical, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outset Medical, Inc. 52 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OM?
As at 21 Nov 2026, Outset Medical, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).
Will OM stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +149.1% from the last close, and Ticker Nerd's factor model ranks Outset Medical, Inc. 52 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OM stock forecast for 2030?
No analyst covering Outset Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.
How has OM stock performed over the past year?
Outset Medical, Inc. returned -36.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Outset Medical, Inc. do?
Outset Medical, Inc. is a medical technology company focused on dialysis care. Its core product, the Tablo Hemodialysis System, is designed to simplify hemodialysis by combining integrated water purification, on-demand dialysate production, software, and connectivity in a compact platform.
About Outset Medical, Inc.
Outset Medical, Inc. is a medical technology company focused on dialysis care. Its core product, the Tablo Hemodialysis System, is designed to simplify hemodialysis by combining integrated water purification, on-demand dialysate production, software, and connectivity in a compact platform. The company also provides related consumables and a data ecosystem that includes tools for healthcare providers, patients, and internal analytics. Outset Medical serves hospitals, dialysis clinics, and home-care settings, supporting dialysis delivery across the continuum of care. The company’s products are positioned to help healthcare providers manage dialysis programs with a more streamlined and technology-enabled workflow. Headquartered in San Jose, California, Outset Medical operates in the renal care and medical equipment markets, where it offers a specialized solution for patients and providers involved in kidney replacement therapy.
CEO Ms. Leslie L. Trigg · 310 employees · United States · https://www.outsetmedical.com